[mAbs] A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs

Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offerimproved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs).However, the translation of these non-natural molecules into successful therapeutics can be hamperedby developability challenges. Here, we systematically analyzed 64 different antibody constructs targetingTumor Necrosis Factor (TNF) which cover 8 distinct molecular format families, encompassing full-lengthantibodies, various types of single chain variable fragments, and bispecifics. Have a look at the paper external page here!